Ludwig Wolf-Dieter, Hildebrandt Martin, Schott Gisela
Arzneimittelkommission der deutschen Arzteschaft, Herbert-Lewin-Platz 1, 10623 Berlin.
Z Evid Fortbild Qual Gesundhwes. 2009;103(3):149-54. doi: 10.1016/j.zefq.2009.02.018.
Numerous studies have addressed the subject of the extent and consequences of financial ties between pharmaceutical companies, academic institutions and clinical researchers. Based on these reports, guidelines for the management of conflicts of interest have been developed which give priority to the patients' welfare on all levels of interaction between doctors and industrial sponsors. The declaration of potential conflicts of interest and strict adherence to guidelines are mandatory to retain the physicians' credibility, reputation, and professional autonomy. Enhanced transparency in the conduct and analysis of clinical trials should be regarded as a valuable tool to uncover and avoid undue influence on clinical trials and derived prescription recommendations.
众多研究探讨了制药公司、学术机构和临床研究人员之间财务关系的程度及后果这一主题。基于这些报告,已制定了利益冲突管理指南,该指南在医生与行业赞助商互动的各个层面都将患者福利置于首位。申报潜在利益冲突并严格遵守指南对于维护医生的信誉、声誉和职业自主性而言是必不可少的。临床试验实施与分析过程中增强透明度应被视为一种有价值的工具,用以发现并避免对临床试验及由此得出的处方建议产生不当影响。